Revenio Group Oyj — Cyborg Score 7/10

Strategic Profile

Strong global demand and successful new product launches drive growth, with selective price increases and rising software revenues enhancing margins. Expansion into the Chinese market and successful product launches are set to drive significant future revenue growth. The company differentiates through proprietary iCare technology and clinical software integration.

Cyborg Score Rationale

With a market cap of €512.9M and PE ratio of 27.94, the company commands premium valuation reflecting growth expectations. 2024 revenue of $112M grew 7.2% year-over-year despite net profit margin pressure of -9.7%. The company shows strong competitive positioning but faces margin headwinds requiring strategic optimization.

Top Insights

• iCare brand dominates glaucoma diagnostics with clinical software integration expanding recurring revenue streams
• Geographic diversification across Europe, North America, and emerging Asian markets including China expansion drive long-term growth
• AI-powered screening software (iCare ILLUME) and cloud platforms address early disease detection and digital health trends
• Premium valuation (PE ~28) reflects growth expectations, though recent margin compression warrants monitoring

Named Competitors

• OCT imaging and tonometry devices — Integrated ophthalmic imaging systems
• Perimetry and imaging platforms — Comprehensive eye care diagnostic suite
• Tonometry and retinal imaging — Integrated ophthalmic diagnostic systems

Recent Developments

• (Feb 2026) Q4 2025 earnings released showing continued revenue growth trajectory
• (Jan 2026) Analyst coverage maintained at 9 analysts with positive sentiment on Chinese market expansion
• (2024) Revenue achieved $112M with 7.2% growth despite cost pressures affecting profitability

Open the full interactive Revenio Group Oyj report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.